Evaluating the Tolerability of Combination of Verdinexor and Doxorubicin in Dogs with Cancer

Verdinexor is a chemotherapy drug that has been conditionally approved by the FDA for the treatment of canine lymphoma. Verdinexor is a selective inhibitor of nuclear export (SINE) compound, and this family of drug has demonstrated encouraging results in preclinical studies when combined with other chemotherapeutic drugs. These studies offer encouragement that these types of combinations and clinical results could be achieved in dogs. This study seeks to establish the tolerability of verdinexor in combination with doxorubicin in dogs with cancer. The results of this study could be used to advance the study of this combination of drugs in future clinical trials that focus on a specific cancer types. The study duration is 120 days and consists of a total of 10 hospital visits. The trial is fully funded with no costs to the owner.

ELIGIBILITY CRITERIA:

• Any dog with a measurable cancer that has been diagnosed via biopsy or fine needle aspiration
• Dogs weighing >9 kg
• No previous chemotherapy within 1 week of study entry

PARTICIPATING HOSPITALS

• Pet Emergency and Specialty Center of Marin, San Rafael, CA
• Premier – Orland Park, Orland Park, IL
• The Oncology Service – Richmond, VA
• Veterinary Specialty Hospital, Sorrento Valley, San Diego, CA
• Veterinary Specialty Hospital, North County, San Marcos, CA